Latest News

NORTH JERSEY CHAMBER OF COMMERCE: Crunch Lunch Networking on Jan. 31

Join us for a lunch date “crunching” around in support of our member restaurant communities and what we do best, networking!


In the aftermath of the 2018 midterm elections, the Democratic Party won the majority in the House of Representatives and will have a preponderance of voting influence in selecting the next Speaker of the House.

DAIICHI SANKYO, INC: Carrie Ann Inaba Partners with Daiichi Sankyo, Inc. to Encourage Americans to “Get Iron Informed”

Daiichi Sankyo, Inc. today announced a partnership with dancer, choreographer and TV host Carrie Ann Inaba on Get Iron Informed, a campaign to raise awareness of Iron Deficiency Anemia (IDA) – a common type of anemia that can occur when iron levels are insufficient to generate healthy red blood cells.2 Ms. Inaba is partnering with Daiichi Sankyo, Inc. to share her personal experience living with the condition, and reach those who are undiagnosed and at risk so they understand the importance of speaking to their doctor about their iron levels.

MERCK: Merck to Hold Fourth-Quarter and Full-Year 2018 Sales and Earnings Conference Call on February 1

Merck (NYSE: MRK), known as MSD outside the United States and Canada, will hold its fourth-quarter and full-year 2018 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EST on Friday, Feb. 1. During the call, company executives will provide an overview of Merck’s performance for the quarter.

KONICA MINOLTA BUSINESS SOLUTIONS U.S.A., INC: Konica Minolta Launches The MOBOTIX Intelligent Video Security Solution

Konica Minolta Business Solutions U.S.A., Inc. (Konica Minolta) today announced the launch of its MOBOTIX Intelligent Video Security Solution.

DAIICHI SANKYO INC.: Daiichi Sankyo Initiates Pivotal Phase 3 Trial of [Fam-] Trastuzumab Deruxtecan (DS-8201) in HER2 Low Metastatic Breast Cancer

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that the first patient has been dosed in DESTINY-Breast04, a global pivotal phase 3 study evaluating the safety and efficacy of [fam-] trastuzumab deruxtecan (DS-8201), an investigational HER2 targeting antibody drug conjugate (ADC), in patients with HER2 low, unresectable and/or metastatic breast cancer previously treated with standard chemotherapy.

ASB RESOURCES: What's New in Business Intelligence for 2019

With the rising complexity of the business intelligence environment, the identification of trends is a key factor in effective decision-making.

HONEYWELL INTERNATIONAL: Honeywell to Present at Cowen and Company 40th Annual Aerospace/Defense and Industrials Conference

Honeywell (NYSE: HON) announced Pieter Krynauw, President of Honeywell Intelligrated, will present at the Cowen and Company 40th Annual Aerospace/Defense and Industrials Conference in New York City on Thursday, February 7 at 10:00 a.m. EST.

BD: BD Announces Webcast of Annual Meeting of Shareholders

BD (Becton, Dickinson and Company) (NYSE: BDX), a global medical technology company, announced today that it will host a live webcast of its Annual Meeting of Shareholders on Tuesday, January 22, 2019, at 1 p.m. (ET).

NEW JERSEY CHAMBER OF COMMERCE: Statement by N.J. Chamber of Commerce President Tom Bracken on State of the State Address

The New Jersey that Gov. Phil Murphy described in his state of the state message, where everyone can flourish, is one we all can support.

CORPORATE ESSENTIALS: Corporate Essentials’ Holiday Charity: The Results Are In!

This holiday season, in lieu of gifts, Corporate Essentials made donations to Make-A-Wish Foundation New Jersey, Doctors Without Borders and Wounded Warrior Project on behalf of our customers.

OCEAN COUNTY: Contracts for Senior Services Approved by Freeholders

With 173,000 senior citizens calling Ocean County home, the Board of Chosen Freeholders is making certain programs and services tailored to their ever-changing needs are available and easily accessible.

NEW JERSEY CHAMBER OF COMMERCE: Op-Ed: It’s Time to Stop Ignoring the Needs of NJ’s Business Community

The governor wants a fairer economy in New Jersey but companies are bearing the heaviest burden of delivering it.

MERCK: Merck Exercises Option for NGM Bio’s Investigational Insulin Sensitizer, NGM313, for the Treatment of NASH and Type 2 Diabetes

Merck (NYSE:MRK), known as MSD outside the United States and Canada, and NGM Biopharmaceuticals, Inc. (NGM) today announced that Merck has exercised its option to license NGM313, an investigational monoclonal antibody agonist of the β-Klotho/FGFR1c receptor complex that is currently being evaluated for the treatment of nonalcoholic steatohepatitis (NASH) and type 2 diabetes.

MERCK: Merck’s KEYTRUDA® (pembrolizumab) Receives Five New Approvals in Japan, Including in Advanced Non-Small Cell Lung Cancer (NSCLC), as Adjuvant Therapy for Melanoma, and in Advanced Microsatellite Instability-High (MSI-H) Tumors

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that KEYTRUDA, Merck’s anti-PD-1 therapy, has simultaneously received five new approvals from the Japan Pharmaceuticals and Medical Devices Agency (PMDA), including three expanded uses in advanced non-small lung cancer (NSCLC), one in melanoma, as well as a new indication in advanced microsatellite instability-high (MSI-H) tumors.

Metro Business Network